Patent 8679505 was granted and assigned to Novartis on March, 2014 by the United States Patent and Trademark Office.
An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunization. These polypeptides may optionally be used in combination with S. aureus saccharides.